Prevalence and risk factors of nonalcoholic fatty liver disease, high-risk nonalcoholic steatohepatitis, and fibrosis among lean United States adults: NHANES 2017-2020

被引:3
|
作者
Kalligeros, Markos [1 ,6 ]
Vassilopoulos, Stephanos [1 ]
Vassilopoulos, Athanasios [1 ]
Shehadeh, Fadi [1 ,2 ]
Lazaridou, Ingrid [1 ]
Mylonakis, Eleftherios [3 ]
Promrat, Kittichai [4 ]
Wands, Jack R. [5 ]
机构
[1] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Dept Med, Providence, RI USA
[2] Natl Tech Univ Athens, Dept Elect & Comp Engn, Athens, Greece
[3] Houston Methodist Hosp, Dept Med, Houston, TX USA
[4] Providence VA Med Ctr, Div Gastroenterol & Hepatol, Providence, RI USA
[5] Brown Univ, Warren Alpert Med Sch, Liver Res Ctr, Providence, RI USA
[6] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Med, Providence, RI 02903 USA
来源
ANNALS OF GASTROENTEROLOGY | 2023年 / 36卷 / 06期
关键词
Nonalcoholic fatty liver disease; nonalcoholic steatohepatitis; fibrosis; NHANES;
D O I
10.20524/aog.2023.0840
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Nonalcoholic fatty liver disease (NAFLD) is a growing public health concern worldwide. Early detection and management of modifiable risk factors are critical to mitigating its impact. This study aimed to investigate the prevalence and risk factors of NAFLD, nonalcoholic steatohepatitis (NASH), and fibrosis among lean adults in the United States (US), using the latest National Health and Nutrition Examination Survey (NHANES) dataset from 2017-2020. Methods Using controlled attenuation parameter scores of >= 285 dB/m, we assessed the age-adjusted prevalence of lean NAFLD. To determine the age-adjusted prevalence of high-risk NASH and significant fibrosis, we used the FibroScan-aspartate aminotransferase (FAST) score (cutoffs 0.35 and 0.67) and vibration-controlled transient elastography (liver stiffness measurement >= 8 kPa). Multivariate logistic regression was used to identify potential risk factors.Results We found the age-adjusted prevalence of lean NAFLD to be 6.30%. Among lean US adults, the age-adjusted prevalence of high-risk NASH and significant fibrosis was 1.29% and 4.35%, respectively. Older age and metabolic comorbidities, such as hypertension, diabetes, and dyslipidemia were associated with NAFLD and its complications.Conclusion These findings suggest that the prevalence of NAFLD is of concern among lean individuals, particularly those aged 40 and older with metabolic comorbidities, while a targeted approach to screening and risk stratification for hepatic fibrosis upon lean NAFLD diagnosis is warranted.
引用
收藏
页码:670 / +
页数:11
相关论文
共 50 条
  • [31] Comparison of risk factors for nonalcoholic steatohepatitis and advanced fibrosis between patients with obese and non-obese nonalcoholic fatty liver disease
    Kim, W.
    Joo, S. K.
    Kim, D.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S597 - S597
  • [32] Predictive Risk Factors of Nonalcoholic Fatty Liver Disease in a Lean Chinese Population
    Liu, Lu
    Shi, Xiaolan
    Gao, Jingwen
    Xu, Chunfang
    Liu, Xiaolin
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (12):
  • [33] Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease
    Park, Huiyul
    Yoon, Eileen L.
    Ito, Takanori
    Jo, Ae Jung
    Kim, Mimi
    Lee, Jonghyun
    Kim, Hye-Lin
    Arai, Taeang
    Atsukawa, Masanori
    Kawanaka, Miwa
    Toyoda, Hidenori
    Ishigami, Masatoshi
    Yu, Ming-Lung
    Jun, Dae Won
    Nguyen, Mindie H.
    JAMA NETWORK OPEN, 2023, 6 (08)
  • [34] Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors
    Principi, Mariabeatrice
    Iannone, Andrea
    Losurdo, Giuseppe
    Mangia, Michela
    Shahini, Endrit
    Albano, Francesca
    Rizzi, Salvatore Fabio
    La Fortezza, Rosa Federica
    Lovero, Rosa
    Contaldo, Antonella
    Barone, Michele
    Leandro, Gioacchino
    Ierardi, Enzo
    Di Leo, Alfredo
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (07) : 1589 - 1596
  • [35] Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV
    Michel, Maurice
    Labenz, Christian
    Wahl, Alisha
    Anders, Malena
    Armandi, Angelo
    Huber, Yvonne
    Galle, Peter R.
    Sprinzl, Martin
    Schattenberg, Joern M.
    AIDS, 2022, 36 (12) : 1665 - 1674
  • [36] High prevalence and risk factors for nonalcoholic fatty liver disease in patients with Crohn's disease
    Flores, C.
    Souza, R. K.
    De Bona, L. R.
    Deconto, M. D.
    Arrojo, R. S.
    Gazzoni, F. F.
    Oliveira, T. F.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I364 - I364
  • [37] High prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in type 2 diabetes mellitus
    Thiruppathi, Shankar
    Falck-Ytter, Yngve
    Dasarathy, Srinivasan
    Rogers, Nicholette
    McCullough, Arthur J.
    HEPATOLOGY, 2006, 44 (04) : 660A - 660A
  • [38] Prevalence of Steatotic Liver Disease (MASLD, MetALD, and ALD) in the United States: NHANES 2017-2020
    Kalligeros, Markos
    Vassilopoulos, Athanasios
    Vassilopoulos, Stephanos
    Victor, David w.
    Mylonakis, Eleftherios
    Noureddin, Mazen
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (06) : 1330 - 1332
  • [39] Exploring factors related to clinically advanced fibrosis in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis
    Yu, Anthony
    Ritenour, Alexandra
    Vincent, Jennifer
    Park, Chanhyun
    Rascati, Karen
    Godley, Paul
    POSTGRADUATE MEDICINE, 2024, 136 (01) : 14 - 21
  • [40] Cumulative Social Risk Exposure and Risk of Lean MASLD in US Adults: NHANES 2017-2020
    Boateng, Sarpong
    Ameyaw, Prince A.
    Kasar, Amita
    Njei, Basile
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S1318 - S1319